Miza completes acquisition
Miza Pharmaceuticals, the Toronto, Canada-based, company has completed the acquisition of the pharmaceutical development and manufacturing assets of CCL Pharmaceutical Industries.
CCL provides sterile-fill contract development and manufacturing services to the pharmaceutical, biotechnology and medical device industries. Under the terms of the transaction, CCL will transfer all pharmaceutical product licences, manufacturing assets, approvals and intellectual property, and all customer and vendor contracts to Miza.
The asset-based transaction includes three development and manufacturing facilities located in central and north-west England, employing a workforce of 300 persons.
'The acquisition of CCL's pharmaceutical operations provides Miza with state-of-the-art manufacturing capabilities in both eye care and respiratory-care markets, advanced inhaler-delivery technology and significant development and manufacturing capabilities,' said Miza's ceo, Dr Jack Kachler.
'With its outstanding customer base and diverse distribution channels, the CCL Pharmaceuticals operation will significantly enhance Miza's market presence in North America, Europe and other key markets.'